Dublin-listed pharmaceutical services company Open Orphan has signed a new deal with New York-based Codagenix for the phase one trial of a new Covid-19 vaccine.
The trial, which will evaluate the safety and ability of the vaccine to evoke a repulsions in the immune system, will look at 48 healthy young adult volunteers.
The vaccine is a single-dose, intranasal candidate, and will be trialled at Open Orphan subsidiary Hvivo’s quarantine facility in Whitechapel in London. The trial will begin in early autumn, with initial data expected by the end of the year.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).